In recent years, the advent of the tau tracers 18F‐AV‐1451 (T‐807),818F‐THK‐5351,9 and (2‐((1E,3E)‐4‐(6‐(11C‐methylamino)pyridin‐3‐yl)buta‐1,3‐dienyl)benzo[d]thiazol‐6‐ol) (11C‐PBB310) has increased the interest in tau PET imaging in neurodegenerative diseases, but their clinical utility is not fully known to date. This evidence concerns the gene MAPT and neurodegenerative disease.